Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
Status:
Withdrawn
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Concurrent chemoradiotherapy is the standard treatment for locally advanced non-small cell
lung carcinoma (NSCLC). Different chemotherapy and radiation regimens have been advocated but
in general, cisplatin-doublets are deemed standard of care. Decreasing the overall treatment
time of irradiation by hypofractionation is thought to increase the efficacy. Extensive
experience is available on the combination of daily-dose cisplatin in combination with
hypofractionated radiotherapy. However, no data is available on the safety of cisplatin
doublets and hypofractionated radiotherapy